iShares Biotechnology ETF $IBB Stake Lessened by True Vision MN LLC

True Vision MN LLC lessened its holdings in iShares Biotechnology ETF (NASDAQ:IBB) by 67.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,511 shares of the financial services provider’s stock after selling 9,280 shares during the period. True Vision MN LLC’s holdings in iShares Biotechnology ETF were worth $762,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of IBB. Citigroup Inc. raised its position in iShares Biotechnology ETF by 40.9% during the fourth quarter. Citigroup Inc. now owns 5,242,688 shares of the financial services provider’s stock valued at $884,808,000 after buying an additional 1,521,992 shares during the period. Morgan Stanley boosted its position in iShares Biotechnology ETF by 2.5% during the 4th quarter. Morgan Stanley now owns 3,204,126 shares of the financial services provider’s stock worth $540,760,000 after acquiring an additional 76,978 shares during the period. BNP Paribas Financial Markets boosted its position in iShares Biotechnology ETF by 11.4% during the 4th quarter. BNP Paribas Financial Markets now owns 2,133,461 shares of the financial services provider’s stock worth $360,064,000 after acquiring an additional 218,066 shares during the period. JPMorgan Chase & Co. grew its stake in iShares Biotechnology ETF by 27.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,060,048 shares of the financial services provider’s stock valued at $153,039,000 after acquiring an additional 226,852 shares in the last quarter. Finally, Raymond James Financial Inc. increased its holdings in shares of iShares Biotechnology ETF by 286.2% in the 4th quarter. Raymond James Financial Inc. now owns 994,311 shares of the financial services provider’s stock valued at $167,810,000 after purchasing an additional 736,881 shares during the period. Hedge funds and other institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Price Performance

NASDAQ IBB opened at $173.64 on Monday. The company has a 50 day simple moving average of $170.61 and a 200-day simple moving average of $170.67. iShares Biotechnology ETF has a 52-week low of $123.61 and a 52-week high of $179.64.

iShares Biotechnology ETF Cuts Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, June 18th. Shareholders of record on Monday, June 15th were paid a $0.0238 dividend. This represents a $0.10 annualized dividend and a yield of 0.1%. The ex-dividend date was Monday, June 15th.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.